SAB Biotherapeutics (SABS) Competitors $4.65 +0.75 (+19.23%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends SABS vs. ACHV, RGLS, AGEN, FBIO, CRIS, BOLT, MTEM, AMGN, VRTX, and GILDShould you be buying SAB Biotherapeutics stock or one of its competitors? The main competitors of SAB Biotherapeutics include Achieve Life Sciences (ACHV), Regulus Therapeutics (RGLS), Agenus (AGEN), Fortress Biotech (FBIO), Curis (CRIS), Bolt Biotherapeutics (BOLT), Molecular Templates (MTEM), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), and Gilead Sciences (GILD). These companies are all part of the "biotechnology" industry. SAB Biotherapeutics vs. Achieve Life Sciences Regulus Therapeutics Agenus Fortress Biotech Curis Bolt Biotherapeutics Molecular Templates Amgen Vertex Pharmaceuticals Gilead Sciences Achieve Life Sciences (NASDAQ:ACHV) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings, community ranking and dividends. Which has stronger valuation & earnings, ACHV or SABS? Achieve Life Sciences has higher earnings, but lower revenue than SAB Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAchieve Life SciencesN/AN/A-$29.82M-$1.13-3.27SAB Biotherapeutics$2.24M19.16-$42.19MN/AN/A Is ACHV or SABS more profitable? Achieve Life Sciences has a net margin of 0.00% compared to SAB Biotherapeutics' net margin of -1,450.14%. SAB Biotherapeutics' return on equity of -94.37% beat Achieve Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Achieve Life SciencesN/A -108.30% -65.20% SAB Biotherapeutics -1,450.14%-94.37%-67.26% Do analysts recommend ACHV or SABS? Achieve Life Sciences presently has a consensus price target of $14.80, suggesting a potential upside of 301.08%. SAB Biotherapeutics has a consensus price target of $12.40, suggesting a potential upside of 166.67%. Given Achieve Life Sciences' stronger consensus rating and higher probable upside, research analysts clearly believe Achieve Life Sciences is more favorable than SAB Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Achieve Life Sciences 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33SAB Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals have more ownership in ACHV or SABS? 33.5% of Achieve Life Sciences shares are held by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are held by institutional investors. 2.0% of Achieve Life Sciences shares are held by company insiders. Comparatively, 26.5% of SAB Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more risk and volatility, ACHV or SABS? Achieve Life Sciences has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500. Comparatively, SAB Biotherapeutics has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500. Does the MarketBeat Community prefer ACHV or SABS? Achieve Life Sciences received 307 more outperform votes than SAB Biotherapeutics when rated by MarketBeat users. However, 81.82% of users gave SAB Biotherapeutics an outperform vote while only 70.46% of users gave Achieve Life Sciences an outperform vote. CompanyUnderperformOutperformAchieve Life SciencesOutperform Votes33470.46% Underperform Votes14029.54% SAB BiotherapeuticsOutperform Votes2781.82% Underperform Votes618.18% Does the media prefer ACHV or SABS? In the previous week, Achieve Life Sciences had 1 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 1 mentions for Achieve Life Sciences and 0 mentions for SAB Biotherapeutics. Achieve Life Sciences' average media sentiment score of 1.54 beat SAB Biotherapeutics' score of 0.00 indicating that Achieve Life Sciences is being referred to more favorably in the media. Company Overall Sentiment Achieve Life Sciences Very Positive SAB Biotherapeutics Neutral SummaryAchieve Life Sciences beats SAB Biotherapeutics on 11 of the 16 factors compared between the two stocks. Ad Brownstone ResearchCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.Click here to see the details because I believe a lot of people will get rich. Get SAB Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SABS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SABS vs. The Competition Export to ExcelMetricSAB BiotherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$42.92M$2.94B$5.14B$9.08BDividend YieldN/A1.90%5.09%4.23%P/E RatioN/A46.7390.0517.18Price / Sales19.16415.011,117.00116.99Price / CashN/A182.1042.9637.86Price / Book0.753.894.784.78Net Income-$42.19M-$42.21M$120.31M$225.60M7 Day Performance13.97%-2.15%-1.92%-1.23%1 Month Performance51.47%4.20%11.50%3.36%1 Year Performance532.65%18.39%30.59%16.60% SAB Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SABSSAB Biotherapeutics2.4276 of 5 stars$4.65+19.2%$12.40+166.7%+520.0%$42.92M$2.24M0.00140Gap UpHigh Trading VolumeACHVAchieve Life Sciences2.009 of 5 stars$4.12+0.5%$14.80+259.2%+8.8%$141.69MN/A-3.6320RGLSRegulus Therapeutics2.7405 of 5 stars$1.64+3.8%$10.80+558.5%+20.5%$107.42MN/A-1.4830News CoveragePositive NewsAGENAgenus3.6855 of 5 stars$2.89-5.2%$10.00+246.0%-81.2%$67.80M$160.43M-0.27389FBIOFortress Biotech3.1454 of 5 stars$1.89-2.8%$13.67+625.0%-27.1%$52.04M$62.50M-0.63186CRISCuris2.7846 of 5 stars$3.69+3.4%$23.00+523.3%-74.6%$31.24M$10.26M-0.4849BOLTBolt Biotherapeutics2.4704 of 5 stars$0.52-1.6%$3.50+573.7%-50.5%$19.88M$7.88M-0.31100MTEMMolecular Templates3.1833 of 5 stars$0.39-1.9%N/A-95.7%$2.58M$57.31M-0.1562News CoverageGap DownAMGNAmgen4.4684 of 5 stars$268.41-0.8%$319.68+19.1%-4.3%$144.28B$32.53B34.8626,700Analyst DowngradeGap UpVRTXVertex Pharmaceuticals4.7526 of 5 stars$466.65+0.6%$505.73+8.4%-0.7%$120.18B$9.87B-233.035,400Analyst ForecastAnalyst RevisionNews CoverageGILDGilead Sciences4.4898 of 5 stars$92.80+1.0%$96.43+3.9%+17.8%$115.65B$27.12B1,020.6718,000Insider Trade Related Companies and Tools Related Companies ACHV Competitors RGLS Competitors AGEN Competitors FBIO Competitors CRIS Competitors BOLT Competitors MTEM Competitors AMGN Competitors VRTX Competitors GILD Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SABS) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SAB Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
